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Despite recent advances, cancer remains a leading cause of deathworldwide. In developed
countries, the incidence of colorectal and breast cancer has been stable, but no improve-
ment in prognosis has been observed if the patient presents with metastases at diagnosis.
This fact highlights the importance of therapeutic approaches targeting cellular invasion and
metastasis programs as the next step in cancer treatment. During carcinoma progression
a process called epithelial–mesenchymal transition (EMT) results in enhanced invasion and
motility which is directly linkedwith loss of epithelial polarity and epithelial junctions, migra-
tion permissive cytoskeleton alterations, and the acquisition of mesenchymal properties.
The recent discovery of microRNAs (miRNAs) controlling key cellular pathways has opened
a new era in understanding how EMT pathways are modulated. In this review, we classify
EMT regulating proteins according to their cellular localization (membrane, cytoplasmic,
and nuclear), and summarize the current knowledge on how they are controlled bymiRNAs
and propose potential miRNAs for the transcripts that may control their expression.
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INTRODUCTION
Despite advances in diagnosis and treatment, cancer remains the
second highest cause of death in developing countries (Jemal
et al., 2011). The vast burden of cancer associated morbidity
and mortality is principally attributable to the development of
metastases from the primary tumor site through a complicated
and multistep process whereby cancer cells depart their normal
microenvironment, and disseminate and colonize distant organs.
Even so, the cellular and molecular machinery underlying metas-
tasis is relatively poorly understood, and more effective thera-
peutic strategies are clearly required in order to oppose cancer
dissemination.
Cellular invasion and epithelial–mesenchymal transition
(EMT) programs enable metastasis. EMT is an embryologically
conserved genetic program by which epithelial cells down regulate
intercellular tight junctions, loose polarity, express mesenchy-
mal markers, and manifest a migratory phenotype (Thiery and
Sleeman, 2006). While the signiﬁcance of EMT in gastrulation
and neural crest cell migration during embryogenesis is well-
established, its role in tumor progression and metastasis is still
under investigation (Thiery, 2003). EMT is activated by TGFβ,
FGF, and Notch signaling pathways, which converge to activate
transcription factors that subsequently repress the expression of
epithelial genes. Key transcription factors in this process include
members of the SNAI, Twist, and ZEB families, which suppress
epithelialmarkers and promote expression of mesenchymalmark-
ers, hallmarks of the cellular phenotypic switch that occurs in
EMT. In addition to enhanced migration, these cells acquire stem
cell properties, resistance to apoptosis, undergo cell cycle arrest,
and senescence (Vega et al., 2004; Mejlvang et al., 2007; Ansieau
et al., 2008; Mani et al., 2008; Sayan et al., 2009). As some features
of EMT (such as induction of cell cycle arrest and senescence) are
incompatiblewith successful tumor growth, tumor cells re-acquire
epithelial properties when they form secondary tumors through a
process recognized as mesenchymal–epithelial transition (MET).
In recent years, a growing body of evidence has highlighted the
critical role of EMT and its regulation by microRNAs (miRNA) in
co-ordinating this complex cellular process.
MiRNAs are 18–24nucleotides long phylogenetically conserved
non-coding RNAs that silence target genes by binding with par-
tial speciﬁcity to the 3′ untranslated region (3′UTR) of target
mRNA, thus inhibiting translation or promoting mRNA degra-
dation. Their speciﬁcity is determined by nucleotides 2–8 at the 5′
end, termed the miRNA “seed sequence” (Bartel, 2009). To date,
more than 1400 human miRNAs have been identiﬁed (Sanger
miRBase 17; http://www.miRbase.org/index.shtml), forming less
than 1% of all human genes, potentially regulating more than
10% of all protein coding genes. Crucially, miRNAs can function
as both tumor suppressors and oncogenes, and are implicated in
promoting EMTand cancer stem cell formation, as well as all other
hallmarks of malignancy (Bartels and Tsongalis, 2009).
In light of these recent discoveries, the present article discusses
how invasion and EMT pathways are regulated by miRNAs. We
have classiﬁed key proteins involved in EMT and invasion pro-
grams according to their localization (cell membrane, cytoplasm,
or nucleus) and point out potential/validated miRNAs regulat-
ing their expression and highlight critical knowledge gaps that
remain to be addressed to enable improved understanding of
the molecular mechanisms behind EMT and metastasis. A list of
experimentally validated and in silico identiﬁed miRNAs regulat-
ing key proteins involved in invasion–metastasis programs can
be found in Table 1. We used TargetScan (V 5.2; Lewis et al.,
2005), PicTar (Krek et al., 2005), and Microcosm (V 5.0) pro-
grams to identify potential miRNAs targeting EMT associated
transcripts, and have listed the evolutionary conserved and high
scoring ones.
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Table 1 | Predicted/validated microRNAs targeting the expression of
invasion/EMT related proteins.
Category Target
molecule
Validated
miRNAs
Proposed
miRNAs
Cell
adhesion
E-cadherin miR-9
Cell
Adhesion
N-cadherin miR-199*,
-218*
Polarity Par-3 miR-491-5p
Polarity Par-4 miR-451 miR-2, -304
Cytoplasmic FAK miR-138
Cytoplasmic Src miR-205 miR-9, -132
Cytoplasmic PTEN miR-s-17-92, -26a,
-106b/25, -155, -214, -21
Cytoplasmic APC miR-135 miR-27*,
-153*, -125*
Cytoplasmic/
nuclear
β-Catenin miR-200a miR-320*, -214
Nuclear ZEB1 miR-200, miR-205
Nuclear ZEB2 miR-200, miR-205 miR-153
Nuclear SNAI1 miR-204 miR-30*, -153
Nuclear SNAI2 miR-124a miR-10b, -203
Nuclear TWIST1 miR-33, -337,
-151*
*miRNA was identiﬁed by multiple algorithms.
CELL ADHESION AND POLARITY PROTEINS
CADHERIN SWITCH
Cell to cell adhesion is an intricately regulated process playing
a pivotal role in tumorigenesis. A hallmark of EMT is tempo-
rary loss of the epithelial cell–cell adhesion molecule E-cadherin,
and concomitant up regulation of N-cadherin; a process termed
the cadherin switch (Tomita et al., 2000). The critical nature of
the “cadherin switch” in EMT is highlighted by studies demon-
strating loss of E-cadherin function alone is sufﬁcient to induce
a metastatic cellular phenotype (Perl et al., 1998), although E-
cadherinmutations are only observed in gastric and lobular breast
cancers (Berx et al., 1998). Regulation of E-cadherin expression
is directly mediated by miR-9 via direct translational inhibition
(Ma et al., 2010). In addition, a more complex and indirect regu-
latory feedback loop modulating E-cadherin expression has been
observed between the miR-200 family members (miR-200, miR-
141, and miR-429), miR-192, miR-205, and the ZEB transcription
factors and is discussed later. Acquisition of N-cadherin is also
critical for maintenance of a mesenchymal phenotype, but there
are limited reports on how N-cadherin transcript is regulated.
We have identiﬁed miR-199 and 218 as potential regulators of N-
Cadherin translation and are currently investigating this potential
regulation.
EPITHELIAL POLARITY
Another key feature of invasion and EMT is the loss of apical–
basal polarity. Maintenance of cellular polarity is vital to achieve
organization of complex epithelial tissues and its loss is a com-
mon occurrence in cancer (Royer and Lu, 2011). The critical role
of three complexes, namely Scribble, Crumbs, and Par, has been
highlighted in maintaining epithelial polarity, of which the Par
complex is best understood and implicated in EMT (Zhou et al.,
2010; Royer and Lu, 2011). Par-3 depletion disrupts the forma-
tion of tight junctions favoring mesenchymal transformation in
mammalian cells. Evidence of Par complex regulation by miR-
NAs comes from studies demonstrating that TGFβ signaling, a
key inducer of EMT, down regulates Par-3 by inducing expres-
sion of miR-491-5p in renal tubular epithelial cells (Zhou et al.,
2010). Furthermore, Par-4 (also known as LKB1) is regulated by
miR-451 and is mutated in one-third of lung adenocarcinomas
(Roy et al., 2010). A recent study demonstrated that increased
miR-451 expression modulates LKB1/AMPK signaling favoring
cellular migration and resistance to apoptosis, and is associ-
ated with reduced patient survival (Godlewski et al., 2010). We
have identiﬁed miR-2 and 304 as potential regulators of Par-4
(Table 1).
CYTOPLASMIC REGULATORS OF EMT
Within a tissue, cells must adhere not only to one another, but
also to the extra-cellular matrix (ECM) that surrounds them. The
integrin family of proteins are key regulators of cell–ECM inter-
actions and function as both adhesion molecules and receptors
(Dalmay and Edwards, 2006; Parsons et al., 2010). Altered inte-
grin expression is a frequent observation in cancers, particularly
at the invasive front, providing evidence of their role as regula-
tors of invasion and EMT. Integrin signaling induces changes in
dynamic polymerization of actin cytoskeleton and maintenance
of mesenchymal status. Modulation of actin polymerization by
miRNAs via integrin signaling and the Rho family of GTPases
(Rho, Rac, and CDC42) has been considered in detail in previous
reviews and hence is not discussed here (Valastyan and Weinberg,
2011).
Focal adhesion kinase (FAK)–Src complex acts as a sensor to
relate the signals from ECM (via integrin engagement) and recep-
tor tyrosine kinases (RTKs) to the cytoskeleton, and plays a com-
plex role in regulating EMT (Avizienyte and Frame, 2005). Src–
FAK complex impose multiple pro-metastatic inﬂuences, includ-
ing cadherin switch, lamellipodia formation, and secretion of
matrix metalloproteases (Mitra and Schlaepfer, 2006). No miR-
NAs have been identiﬁed to date as direct post-transcriptional
repressors of FAKs in the cancer setting however miR-138 was
found to regulate FAK protein levels during osteoblast differentia-
tion (Eskildsen et al., 2011).Another developmental study assigned
a function of miR-488 as a key regulator of FAKs during differ-
entiation of chondrocytes (Song et al., 2011). Additionally the
genomic locus of FAK encodes miR-151, a miRNA that regulates
RhoGDIA expression, a GTPase regulatory protein that inﬂuences
actin polymerization. Expression of FAK results in co-expression
of miR-151, which indirectly suppresses FAK mediated signaling
cascades involved in cytoskeletal actin polymerization, thus mod-
ulating cellular metastatic behavior (Ding et al., 2010). On the
other hand, there is only one study assigning a function to a
miRNA in controlling Src protein abundance. An inverse corre-
lation has been observed between Src family kinases (SFKs) and
miR-205 expression in renal carcinomas and binding of miR-205
to the 3′-UTR of Src mRNA was validated. Over-expression of
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miR-205 resulted in susceptibility to apoptosis, reduced colony
formation and invasion, both in vitro and in vivo (Majid et al.,
2011).
The Phosphatase and TENsin homolog (PTEN) tumor sup-
pressor gene encodes for a lipid phosphatase and is mutated
in varying frequencies in almost all tumors. PTEN suppression
contributes to EMT in part by modulation of the Akt/β-catenin
pathway.β-Cateninplays adual role in cellular physiologyby form-
ing a core structural component of cadherin junctions and also
functions as a transcription factor inﬂuencing gene expression.
Cytoplasmic β-catenin is modulated by 3 primary mechanisms,
(1) Down regulation of E-cadherin during EMT results in break-
down of cadherin junctions resulting in cytoplasmic and nuclear
β-Catenin accumulation, (2) activated receptor tyrosine kinase
signaling suppresses PTEN activity, subsequently activating the
Akt/β-catenin pathway, and (3) Activation of Wnt/Frizzled signal-
ing removes axin from axin/APC/β-catenin/GSK3β complex and
inhibits glycogen-synthase kinase (GSK3β) dependent phospho-
rylation of β-catenin, thus promoting its proteosomal degradation
Accumulation of β-catenin in nucleus facilitates gene expres-
sion associated with cellular proliferation, transformation, and
invasion.
Several miRNAs have been reported to inﬂuence tumorigene-
sis by down regulating PTEN translation, including, miR-17-92
in lymphoproliferative disease (Xiao et al., 2008), miR-19a in
leukemia and Cowden’s syndrome (Calin et al., 2004; Pezzolesi
et al., 2008), miR-26a in high grade glioma (Huse et al., 2009),
miR-106b/25 in prostate tumorigenesis (Poliseno et al., 2010a),
miR-155 in hepatic carcinogenesis (Wang et al., 2009), miR-214
in ovarian cancer (Yang et al., 2008), and miR-21 in multiple
cancers (Krichevsky and Gabriely, 2009). Among these, miR-21
was shown to be upregulated by the potent EMT inducer, TGFβ
(Krichevsky and Gabriely, 2009). Poliseno et al. (2010b) have
identiﬁed PTENP1, a pseudo-gene that acts as a decoy to PTEN
targeting miRNAs, and thus promoting PTEN function. The rel-
evance of this regulatory mechanism in cancer has been further
supported by focal loss of the PTENP1 gene in sporadic colorectal
cancer (Poliseno et al., 2010b).
Other than PTEN, the mRNAs of the proteins in the
axin/APC/β-catenin/GSK3β complex are also targetedbymiRNAs.
MiR-200a takes part in a negative feedback loopwith the ZEB fam-
ily of transcription factors, thusmodulating the cadherin complex,
and is also involved in direct translational repression of β-catenin
mRNA in meningiomas (Saydam et al., 2009). We also identiﬁed
miR-320 as a potential regulator of β-catenin. The miR-135 fam-
ily target the 3′-UTR of APCmRNA, subsequently increasingWnt
signaling by stabilizing β-catenin (Nagel et al., 2008). Using at least
2 different algorithms, we noted that the 3′UTR of APC contains
putative binding sites for miR-27, -153, and -125.
TRANSCRIPTION FACTORS REGULATING EMT
The SNAI and ZEB family of transcription factors (Snai1, Slug,
ZEB1, and ZEB2) are highly conserved zinc ﬁnger transcription
repressors implicated in embryonic development and tumori-
genesis. They bind to E-box like promoter elements in DNA,
consequently inﬂuencing gene expression. The role of ZEB factors
in many human cancers is well-established and corroborates well
with the phenotypic switch brought about by E-cadherin loss
and other EMT features such as chemoresistance (Browne et al.,
2010). In silico analysis of the 3′-UTR region of ZEB family
transcripts has revealed 17 conserved miR-200 family binding
sites; a ﬁnding supported by the well-established role of the
miR-200 family in regulating EMT (Burk et al., 2008; Gregory
et al., 2008; Korpal et al., 2008; Park et al., 2008). MiR-200-ZEB
regulation also stabilizes either the epithelial or mesenchymal
phenotype (Brabletz and Brabletz, 2010). During embryogene-
sis, Slug expression is regulated by miR-124a and over-expression
is associated with impaired migration and stem cell formation
(Lee et al., 2010). MiR-204 has recently been recognized as a
direct post-transcriptional repressor of Snai1 mRNA and con-
sistent with its postulated tumor suppressive role, was found
to be under expressed in different cancer cell lines. Attenu-
ated expression of miR-204 resulted in loss of cell–cell adhesion
supporting the EMT related properties of Snai1 (Wang et al.,
2010).
Twist proteins (Twist 1 and 2) are basic Helix-Loop-Helix
transcription factors that play an important role in neural crest
formation during embryogenesis. Similar to ZEB and the SNAI
family, they are potent inducers of EMT and markers of stem
cell status. Twist transcription factor over-expression has been
reported in multiple solid tumors and is associated with early
metastasis and poor clinical outcome (Ansieau et al., 2010). There
are no reports proposing a direct post-transcriptional control
of TWIST family proteins by a miRNA but we have identi-
ﬁed several that may potentially modulate expression of Twist1
(Table 1).
CONCLUSION
A better understanding of the complexities of tumor cell invasion,
EMT, and MET, are critical for the development of more effective
treatments for metastatic cancer. In recent years, a growing num-
ber of publications have attested to the link between miRNAs and
these mission critical processes during cancer dissemination, and
we have summarized many of these in the present manuscript.
Given the importance of the process of metastasis in determining
cancer speciﬁc outcomes, a working knowledge of the miRNAs
implicated in these processes is likely to be valuable to all sci-
entists and clinicians dealing with human cancer. We and others
consider that acquisition of the migratory properties observed
during metastasis requires hierarchical changes in gene expres-
sion, some of which are controlled by miRNAs. Here, we have
condensed much of this early work, and highlight key deregu-
lated miRNAs targeting molecules involved in cell–cell adhesion,
cytoskeletal rearrangement, Wnt signaling, and transcriptional
control of EMT. In the future, a more complete dissection of
the pathways controlled by these deregulated miRNAs may offer
new insights on metastasis, and highlight promising areas for the
development of novel anti-cancer therapies.
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